Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting

Journal of Nuclear Medicine

Volumn 49, Issue 1, 2008, Pages 158-163

  Goldenberg, David M ^a,b,c,d   Rossi, Edmund A ^b   Sharkey, Robert M ^a   McBride, William J ^c   Chang, Chien Hsing ^b,c  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b IBC Pharmaceuticals Inc   (United States)

^c IMMUNOMEDICS INC   (United States)

^d GARDEN STATE CANCER CENTER   (United States)

Author keywords

Bispecific antibodies; Cancer; PET; Pretargeting; Radioimmunodetection; Radioimmunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; DOCKING PROTEIN; FLUORODEOXYGLUCOSE F 18; HAPTEN PROTEIN Y 90; IMMUNOGLOBULIN F(AB) FRAGMENT; MICROTUBULE ASSOCIATED PROTEIN 2; MONOCLONAL ANTIBODY; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM 90;

ANTIBODY LABELING; CANCER DIAGNOSIS; CANCER THERAPY; COLON CANCER; DIAGNOSTIC IMAGING; DIMERIZATION; DRUG DISTRIBUTION; HUMAN; IMAGE ANALYSIS; NONHUMAN; PANCREAS CANCER; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

A KINASE ANCHOR PROTEINS; ANIMALS; ANTIBODIES, BISPECIFIC; COLONIC NEOPLASMS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; IMMUNOGLOBULIN FAB FRAGMENTS; LUNG NEOPLASMS; MICE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN STRUCTURE, TERTIARY; RADIOIMMUNOTHERAPY; TRANSPLANTATION, HETEROLOGOUS;

EID: 37649020163     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.046185     Document Type: Review

References (43)

1. Goldenberg DM, Sharkey RM. Novel radiolabeled antibody conjugates. Oncogene. 2007;26:3734-3744.
2. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin. 2006;56:226-243.
3. Sharkey RM, Goldenberg DM. Advances in radioimmunotherapy in the age of molecular engineering and pretargeting. Cancer Invest. 2006;24:82-97.
4. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823-834.
5. Sharkey RM, Karacay H, Cardillo TM, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res. 2005;11(19 pt 2):7109s-7121s.
6. Moosmayer D, Berndorff D, Chang CH, et al. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors. Clin Cancer Res. 2006;12:5587-5595.
7. Karacay H, Brard PY, Sharkey RM, et al. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res. 2005;11:7879-7885.
8. Sharkey RM, Cardillo TM, Rossi EA, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med. 2005;11:1250-1255.
9. Sharkey RM, Karacay H, Chang CH, McBride WJ, Horak ID, Goldenberg DM. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia. 2005;19:1064-1069.
10. Cardillo TM, Karacay H, Goldenberg DM, et al. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy. Clin Cancer Res. 2004;10:3552-3561.
11. Sharkey RM, Karacay H, Richel H, et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res. 2003;9(10 pt 2):3897s-3913s.
12. Sharkey RM, McBride WJ, Karacay H, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res. 2003;63:354-363.
13. 124I-labeled hapten-peptide. J Nucl Med. 2006;47:1678-1688.
14. Sharkey RM, Karacay H, Vallabhajosula S, et al. Molecular imaging with pretargeted immunoSPECT and immunoPET in a model of metastatic colonic carcinoma. Radiology. 2008;246:497-507.
15. Baillie GS, Scott JD, Houslay MD. Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett. 2005;579:3264-3270.
16. Wong W, Scott JD. AKAP signalling complexes: focal points in space and time. Nat Rev Mol Cell Biol. 2004;5:959-970.
17. Walsh DA, Perkins JP, Krebs EG. An adenosine 3′,5′- monophosphate-dependant protein kinase from rabbit skeletal muscle. J Biol Chem. 1968;243:3763-3765.
18. Taylor SS. cAMP-dependent protein kinase: model for an enzyme family. J Biol Chem. 1989;264:8443-8446.
19. Scott JD. Cyclic nucleotide-dependent protein kinases. Pharmacol Ther. 1991;50:123-145.
20. Newlon MG, Roy M, Morikis D, et al. The molecular basis for protein kinase A anchoring revealed by solution NMR. Nat Struct Biol. 1999;6:222-227.
21. Scott JD, Stofko RE, McDonald JR, Comer JD, Vitalis EA, Mangili JA. Type II regulatory subunit dimerization determines the subcellular localization of the cAMP-dependent protein kinase. J Biol Chem. 1990;265:21561-21566.
22. Lohmann SM, DeCamilli P, Einig I, Walter U. High-affinity binding of the regulatory subunit (RII) of cAMP-dependent protein kinase to microtubule-associated and other cellular proteins. Proc Natl Acad Sci USA. 1984;81:6723-6727.
23. Carr DW, Stofko-Hahn RE, Fraser ID, et al. Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif. J Biol Chem. 1991;266:14188-14192.
24. Alto NM, Soderling SH, Hoshi N, et al. Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring. Proc Natl Acad Sci USA. 2003;100:4445-4450.
25. Colledge M, Scott JD. AKAPs: from structure to function. Trends Cell Biol. 1999;9:216-221.
26. Newlon MG, Roy M, Morikis D, et al. A novel mechanism of PKA anchoring revealed by solution structures of anchoring complexes. EMBO J. 2001;20:1651-1662.
27. Chmura AJ, Orton MS, Meares CF. Antibodies with infinite affinity. Proc Natl Acad Sci USA. 2001;98:8480-8484.
28. Chang CH, Rossi EA, Goldenberg DM. The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res. 2007;13(18 suppl):5586s-5591s.
29. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res. 1995;55(suppl):5935s-5945s.
30. Losman MJ, Novick KE, Goldenberg DM, Monestier M. Mimicry of a carcinoembryonic antigen epitope by a rat monoclonal anti-idiotype antibody. Int J Cancer. 1994;56:580-584.
31. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med. 2005;46(suppl 1):115S-127S.
32. Goodwin DA, Meares CF, David GF, et al. Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals. Int J Rad Appl Instrum B. 1986;13:383-391.
33. Reardan DT, Meares CF, Goodwin DA, et al. Antibodies against metal chelates. Nature. 1985;316:265-268.
34. Rossi EA, Chang CH, Losman MJ, et al. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res. 2005;11(suppl):7122s-7129s.
35. Rossi EA, Sharkey RM, McBride W, et al. Development of new multivalentbi-specific agents for pretargeting tumor localization and therapy. Clin Cancer Res. 2003;9(suppl):3886s-3896s.
36. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989;30:1358-1366.
37. Boerman OC, Kranenborg MH, Oosterwijk E, et al. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res. 1999;59:4400-4405.
38. Goodwin DA, Meares CF, McTigue M, et al. Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. J Nucl Med. 1992;33:2006-2013.
39. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA. 2006;103:6841-6846.
40. Gold DV, Lew K, Maliniak R, Hernandez M, Cardillo T. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer. 1994;57:204-210.
41. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705-1711.
42. 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med. 2006;47:247-255.
43. Mirallie E, Vuillez JP, Bardet S, et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab. 2005;90:779-788.